Quarterly report pursuant to Section 13 or 15(d)

Collaborative Arrangements - Strategic Collaboration and License Agreement (Details)

v3.20.2
Collaborative Arrangements - Strategic Collaboration and License Agreement (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Mar. 31, 2020
Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Contract with customer, liability $ 4,056   $ 4,056     $ 2,044
Revenue recognized 18,385 $ 21,906 48,023 $ 49,808    
Takeda [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Contract with customer, liability 1,900   1,900      
Revenue recognized $ 2,600   $ 10,600      
Takeda [Member] | Up-front Payment [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Contract with customer, liability         $ 8,500  
Takeda [Member] | Research and Development Reimbursement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Contingent receivable         18,300  
Takeda [Member] | Milestone Payment Per Target Gene [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Contingent receivable         $ 100,000